Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
Clinical trial NCT06762080 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06762080
- Sponsor
- Guangzhou Medical University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-07
- Primary completion
- 2026-07-30
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.